CN114097888A - Formula milk powder for premature infants and preparation method thereof - Google Patents
Formula milk powder for premature infants and preparation method thereof Download PDFInfo
- Publication number
- CN114097888A CN114097888A CN202111555693.7A CN202111555693A CN114097888A CN 114097888 A CN114097888 A CN 114097888A CN 202111555693 A CN202111555693 A CN 202111555693A CN 114097888 A CN114097888 A CN 114097888A
- Authority
- CN
- China
- Prior art keywords
- formula
- milk powder
- milk
- oligosaccharide
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dairy Products (AREA)
Abstract
The invention relates to the field of food engineering, in particular to formula milk powder for premature infants and a preparation method thereof. The formula milk powder is prepared by taking raw milk as a main raw material and adding casein glycomacropeptide, oligosaccharide and other ingredients; based on 100g of formula milk powder, the content of casein glycomacropeptide is 1-6g, and the content of oligosaccharide is 2-9 g. The casein glycomacropeptide is added in the formula of the milk powder, and the milk powder is rich in sialic acid, so that the content of sialic acid in the formula milk powder of the premature infant is far higher than that of the milk powder of the premature infant in the current market, and the intelligence development and the growth development of the infant can be promoted. The oligosaccharide in the formula of the milk powder can promote the intestinal microbial health of the premature infant on one hand, and can be matched with casein glycomacropeptide on the other hand, so that the components of the milk powder in the formula of the premature infant are close to breast milk, and the growth and development of the infant are promoted.
Description
Cross-referencing
The present application claims priority from the patent application entitled "A preterm formula and method of making same," filed 12/18/2020, application number 202011505565.7, the entire contents of which are incorporated herein by reference.
Background
Live-born infants born at gestational age before 37 weeks are known as premature or immature infants. The premature infant has a weight below 2500 g and a head circumference below 33 cm. Although a few premature infants weigh more than 2500 grams, their organ function and adaptability are still inferior to those of term infants. Premature infants have less subcutaneous fat, poor heat preservation capability, weak respiratory function and metabolic function, poorer nutrition absorption and metabolism capability than full-term infants, and certain influence on intelligence development and growth development.
The breast milk is the most ideal natural food for infants, and the abundant nutrient substances in the breast milk provide energy and nutrient requirements for the growth and development of the infants. However, for some people who have insufficient or no breast milk due to their own or external factors, infant formula becomes a major breast milk supplement or substitute for breast milk in the early stage of their infant growth. For premature infants, the formula of the milk powder not only needs to meet the provision of nutrient substances, but also needs to be close to breast milk in nutrition and function, so that the premature infants can obtain good physical growth and neural intelligence development and can fully develop the potential of body health. The current market has difficulty in achieving the effect matched with breast feeding on the milk powder for premature babies.
Therefore, the formula milk powder for the premature infant, which has a feeding effect closer to that of breast milk, has important significance.
Disclosure of Invention
In view of the above, there is a need for a formula milk powder for premature infants and a preparation method thereof, which can make the formula milk powder component closer to breast milk and promote the intelligence development and growth development of premature infants.
In order to achieve the purpose, the invention adopts the following technical scheme:
a formula milk powder for premature infant is prepared from raw milk, casein glycomacropeptide and oligosaccharide; based on 100g of formula milk powder, the addition amount of the casein glycomacropeptide is 1-6g, and the addition amount of the oligosaccharide is 2-9 g.
Casein Glycomacropeptide (CGMP) is a glycopeptide containing sialic acid, is produced by hydrolyzing k-Casein with chymosin in the cheese making process, and has the functional characteristics of inhibiting adhesion of bacteria and viruses, promoting proliferation of bifidobacteria, regulating immune system, combining escherichia coli toxin and cholera toxin, and the like.
Further, in the formula milk powder for premature infants, the raw materials of the formula milk powder also include whey protein powder containing alpha-lactalbumin, desalted whey powder, vegetable oil, fatty acid, lactose, polysaccharides, minerals, vitamins, choline, inositol, taurine, lutein, carnitine and nucleotide.
Further, in the above formula powder for premature infants, the oligosaccharide is galactooligosaccharide and/or fructooligosaccharide. Galacto-oligosaccharide is a functional oligosaccharide with natural properties, and the molecular structure of the galacto-oligosaccharide is generally that 1-7 galactosyl groups are connected on galactose or glucose molecules. Fructo-oligosaccharide is also called sucrose oligosaccharide, and is a mixture of sucrose trisaccharide, sucrose tetrasaccharide, sucrose pentasaccharide, etc. formed by combining 1-3 fructose groups with the fructose group in sucrose through beta fructose group and glycosidic bond. Galacto-oligosaccharides and fructo-oligosaccharides have a positive effect on the regulation of intestinal probiotics.
Further, in the above preterm infant formula, the fatty acids include, but are not limited to, one or more of medium chain triglycerides, docosahexaenoic acid, arachidonic acid; the choline is choline chloride; the carnitine is L-carnitine tartrate.
A method for preparing formula milk powder for premature infants is characterized by comprising the following steps:
step S1: taking raw milk as raw milk, and pre-sterilizing after cleaning the milk; adding other raw materials into the pre-sterilized raw milk and then standardizing the ingredients;
step S2: homogenizing the mixture obtained in the step S1, and sterilizing after homogenizing;
step S3: and (4) concentrating and spray drying the sterilized mixture obtained in the step (S2) to obtain the formula milk powder for premature infants.
Further, in the preparation method of the formula milk powder for premature infants, the pre-sterilization temperature is 85-88 ℃ and the time is 30 s; the homogenizing pressure is 4-18 MPa; the sterilization temperature is 85-97 ℃ and the time is 15 s; the air inlet temperature of spray drying is 150-160 ℃, and the air outlet temperature is 85-90 ℃.
Preferably or alternatively, the raw materials of the preterm formula are as shown in the following table:
| name of raw materials | Dosage, kg/1000 kg milk powder product |
| Raw milk | 100-350 |
| Desalted whey powder | 60-150 |
| Whey protein powder | 10-100 |
| Concentrated whey protein powder (containing casein glycomacropeptide) | 10-50 |
| Vegetable oil | 40-300 |
| Phospholipids | 1-20 |
| Lactose | 50-300 |
| Maltodextrin | 10-100 |
| Galacto-oligosaccharides | 20-120 |
| Fructo-oligosaccharide | 1-20 |
| Xanthophyll | 0.0005-1.0 |
| Lactoferrin | 0.01-2.0 |
| DHA | 0.5-50 |
| Arachidonic acid (ARA) | 1-50 |
| Nucleotide, its preparation and use | 0.01-2.0 |
| Calcium carbonate | 0.5-3.0 |
| Vitamin C | 0.5-6.0 |
| Taurine | 0.1-2.5 |
| Choline chloride | 0.1-3.5 |
| L-carnitine tartrate | 0.05-0.5 |
| Compound nutrition enhancer | 1-30 |
The invention has the beneficial effects that:
(1) the preterm infant formula milk powder provided by the invention is added with a certain amount of casein glycomacropeptide which is a bioactive substance with special functions, and the preterm infant formula milk powder is rich in sialic acid, so that the preterm infant formula milk powder contains enough sialic acid, the sialic acid content of the preterm infant formula milk powder is far higher than that of the preterm infant milk powder on the market at present, and the intelligence development and the growth development of infants can be promoted.
(2) The oligosaccharide is added into the formula milk powder for the premature infant, on one hand, the oligosaccharide can promote the intestinal microbial health of the premature infant, on the other hand, the existence form of sialic acid in the breast milk is mainly combined with the oligosaccharide, and the casein glycomacropeptide and the oligosaccharide in the formula milk powder have the matching effect that the components of the formula milk powder for the premature infant are close to the breast milk, thereby being beneficial to promoting the growth and development of the infant.
Drawings
Fig. 1 is a process flow diagram of a method of preparing a preterm formula of the present invention;
FIG. 2 is a graph comparing the body length index of preterm infants for the milk powder group and the breast milk group of the present invention;
FIG. 3 is a graph comparing the weight index of preterm infants for the milk powder group and the breast milk group of the present invention;
FIG. 4 is a graph comparing the head circumference index of preterm infants for the milk powder group and the breast milk group of the present invention;
FIG. 5 is a graph comparing the relative abundance of Bifidobacterium in feces of preterm infants in the milk powder group and breast milk group of the present invention;
FIG. 6 is a graph comparing the relative abundance of lactococcus in the feces of preterm infants in the milk powder groups of the present invention and breast milk groups.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention clearer, the technical solutions of the present invention will be further clearly and completely described below with reference to the embodiments of the present invention. It should be noted that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Example 1 of the present invention provides a formula milk powder for premature infants.
The formula milk powder for premature infants is prepared by the following method:
step S1, taking raw milk as raw milk, and pre-sterilizing after milk cleaning, wherein the pre-sterilizing temperature is 85-88 ℃, and the pre-sterilizing time is 30S; adding other raw materials into the pre-sterilized raw milk and then standardizing the ingredients;
step S2: homogenizing the mixture obtained in step S1 under 4-18MPa, and sterilizing at 85-97 deg.C for 15S;
step S3: and (4) concentrating and spray drying the sterilized mixture obtained in the step (S2) to obtain the formula milk powder for the premature infant, wherein the air inlet temperature of the spray drying is 150-160 ℃, and the air outlet temperature is 85-90 ℃.
In this example, the other raw materials added include galacto-oligosaccharide, fructo-oligosaccharide, whey protein powder containing α -lactalbumin, concentrated whey protein powder containing casein glycomacropeptide, desalted whey powder, vegetable oil, medium chain triglyceride, docosahexaenoic acid and arachidonic acid, lactose, polysaccharides, minerals, vitamins, choline chloride, inositol, taurine, lutein, L-carnitine tartrate, and nucleotides.
Since it is difficult to extract casein glycomacropeptide having a high purity, it is added in the form of a concentrated whey protein powder.
In this example, the amounts of the respective raw materials added are shown in table 1.
Table 1 example 1 raw material formulation table
The contents of the main nutrients of the formula milk powder for premature infants prepared in this example are shown in table 2.
Table 2 example 1 table of the amounts of major nutrients in preterm infant formula
Example 2
This example provides a preterm formula. The proportions of the ingredients of the preterm formula were substantially the same as in example 1, except that the amounts of casein glycomacropeptide and oligosaccharides added were changed. Based on 100g of formula milk powder, the content of casein glycomacropeptide is 4g, and the content of oligosaccharide (including galacto-oligosaccharide and fructo-oligosaccharide) is 6 g.
The formula milk powder for premature infants is prepared by the following method:
step S1: taking raw milk as raw milk, and pre-sterilizing after milk purification, wherein the pre-sterilizing temperature is 85 ℃ and the time is 30 s; adding casein glycomacropeptide, oligosaccharide and other ingredients into the pre-sterilized raw milk and then standardizing;
step S2: homogenizing and then sterilizing; sterilizing at 90 deg.C for 15 s;
step S3: sterilizing, concentrating, and spray drying; the air inlet temperature of the spray drying is 160 ℃, and the air outlet temperature is 90 ℃.
Example 3
This example provides a preterm formula. The proportions of the ingredients of the preterm formula were substantially the same as in example 1, except that the amounts of casein glycomacropeptide and oligosaccharides added were changed. Based on 100g of formula milk powder, the content of the casein glycomacropeptide is 6g, and the content of the oligosaccharide is 9 g. The preparation method is the same as example 2.
Example 4
This example provides a preterm formula. The proportions of the ingredients of the preterm formula were substantially the same as in example 1, except that the amounts of casein glycomacropeptide and oligosaccharides added were changed. Based on 100g of formula milk powder, the content of the casein glycomacropeptide is 1g, and the content of the oligosaccharide is 4 g. The preparation method is the same as example 2.
Safety of the formula milk powder of the invention
The detection of the product nutritional index, the physicochemical index, the microbial index and the sensory index of the formula milk powder is strictly carried out according to the detection items and the detection methods specified by the national standard of GB 25596-. All indexes of the product reach the national standard, and the product is qualified.
Influence of formula milk powder on growth and development of premature infants
The detection method comprises the following steps: the preterm infant 81 cases were recruited by clinical cohort, wherein 45 cases were fed using the preterm infant formula prepared in example 2 as a milk powder group; 36 cases were breast-fed as breast-milk groups. Detecting and recording the initial indexes of the infant before feeding, wherein the time is recorded as S0; during feeding period, 4 visits were made to the infant for growth and development indexes including body length (cm), body weight (g) and head circumference (cm) (S1/S2/S3/S4), and the safety and tolerance of the product were evaluated.
And (3) detection results: FIG. 2 is a graph of body length comparison data for the powdered milk group and the breast milk group in 4 visits; FIG. 3 is a graph of body weight comparison data for the powdered milk group and the breast milk group over 4 follow-ups; FIG. 4 is a graph of head circumference comparison data for the powdered milk group and the breastfeeding group for 4 follow-ups; as can be seen from fig. 2 and 4, the milk powder group and the breast milk group have no significant difference (p > 0.05). As can be seen from fig. 3, the body weight of the breast milk group was higher than that of the powdered milk group (p <0.05) at the first follow-up visit (S1), and there was no significant difference between the powdered milk group and the breast milk group at the subsequent follow-up visit (p > 0.05). This demonstrates that the feeding effect of the formula milk powder prepared in example 1 of the present invention is comparable to that of breast milk. Meanwhile, no side effect is found when the milk powder is fed to the premature infant, which indicates that the milk powder has good safety and tolerance.
Effect of the formula milk powder of the invention on the intestinal probiotic flora of preterm infants
Test subjects: after approval of ethical committee, a parturient and a corresponding neonate who delivered at 37 weeks gestational age and had no complications were selected as experimental subjects, and a neonate and a corresponding parturient who suffered from congenital malformation, congenital neurogenetic abnormality, metabolic abnormality and other diseases, and a parturient and a corresponding neonate who had a long-term medication history during pregnancy or could not collect colostrum within 5 days after delivery were excluded. The legal representative of each subject can correctly understand the protocol.
The test method comprises the following steps: the breast milk group (C) was selected as 50 test subjects, and the milk powder group (G) was selected as 30 test subjects. The preterm infants in the breast-milk group were breast-fed, and the preterm infants in the milk powder group were fed with the preterm formula prepared in example 2. Feces were collected from each group of preterm infants at 0 days postpartum (T1), 7 days postpartum (T2), 14 days postpartum (T3) and 28 days postpartum (T4). The collected fecal samples were transported at 4 ℃ and stored at-80 ℃.
Total DNA of bacterial genomes in feces was extracted from 100mg of the feces samples using Qiagen Stool Kits (Qiagen, Valencia, Calif.). After quantification by NanoDrop, the V3-V4 gene fragment on the bacterial genome was amplified by PCR (the primer sequences used were: 341F: SEQ ID No. 1; 805R: SEQ ID No.2), and the amplified product was subjected to construction of a sequencing library and sequencing by Illumina HiSeq. The above procedure quantifies the flora diversity and abundance in fecal samples as the number of Operational Taxa (OTUs), and further, the species of each flora are annotated in conjunction with the RDP 16s database.
And (3) test results: the relative abundance data of bifidobacterium (as shown in fig. 5) and lactococcus (as shown in fig. 6) in the fecal samples were selected as representative data for the evaluation of the status of the intestinal probiotic flora of preterm infants.
As can be seen from fig. 5 and 6, the relative abundance of bifidobacterium in the stage T4 of the milk powder group was significantly higher than that of the breast milk group, and the relative abundance of lactococcus in the stages T2-T4 of the milk powder group was significantly increased compared to that of the breast milk group. The above results demonstrate that by feeding the formula provided by the present invention to a preterm infant, the probiotic abundance in the feces of the preterm infant is significantly increased. Compared with breast milk, the formula milk powder provided by the invention can better promote the proliferation of probiotics in the intestinal tract of the premature infant and is more beneficial to the health of the intestinal flora of the premature infant.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
SEQUENCE LISTING
<110> Hebei ternary food Co., Ltd
<120> formula milk powder for premature infant and preparation method thereof
<130> 1
<150> 202011505565.7
<151> 2020-12-18
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 17
<212> DNA
<213> artificial sequence
<220>
<221> misc_feature
<222> (9)..(9)
<223> n is a, c, g, or t
<400> 1
cctacgggng gcwgcag 17
<210> 2
<211> 21
<212> DNA
<213> artificial sequence
<400> 2
gactachvgg gtatctaatc c 21
Claims (6)
1. The formula milk powder for premature infants is characterized in that the formula milk powder comprises raw milk, casein glycomacropeptide and oligosaccharide; based on 100g of formula milk powder, the addition amount of the casein glycomacropeptide is 1-6g, and the addition amount of the oligosaccharide is 2-9 g.
2. The preterm infant formula of claim 1, wherein the raw materials of the formula further comprise whey protein powder containing α -lactalbumin, desalted whey powder, vegetable oil, fatty acids, lactose, polysaccharides, minerals, vitamins, choline, inositol, taurine, lutein, carnitine, nucleotides.
3. The preterm infant formula of claim 1, wherein the oligosaccharide is galacto-oligosaccharide and/or fructo-oligosaccharide.
4. The preterm infant formula powder of claim 2, wherein the fatty acids comprise one or more of medium chain triglycerides, docosahexaenoic acid, arachidonic acid; the choline is choline chloride; the carnitine is L-carnitine tartrate.
5. The method of preparing preterm infant formula according to claim 1, comprising the steps of:
step S1: taking raw milk as raw milk, and pre-sterilizing after cleaning the milk; adding other raw materials into the pre-sterilized raw milk and then standardizing the ingredients;
step S2: homogenizing the mixture obtained in the step S1, and sterilizing after homogenizing;
step S3: and (4) concentrating and spray drying the sterilized mixture obtained in the step (S2) to obtain the formula milk powder for premature infants.
6. The method of preparing preterm infant formula according to claim 5, wherein the pre-sterilization temperature is 85 ℃ to 88 ℃ for 30 s; the homogenizing pressure is 4-18 MPa; the sterilization temperature is 85-97 ℃ and the time is 15 s; the air inlet temperature of spray drying is 150-160 ℃, and the air outlet temperature is 85-90 ℃.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011505565.7A CN112640957A (en) | 2020-12-18 | 2020-12-18 | Formula milk powder for premature infants and preparation method thereof |
| CN2020115055657 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114097888A true CN114097888A (en) | 2022-03-01 |
Family
ID=75354989
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011505565.7A Pending CN112640957A (en) | 2020-12-18 | 2020-12-18 | Formula milk powder for premature infants and preparation method thereof |
| CN202111555693.7A Pending CN114097888A (en) | 2020-12-18 | 2021-12-17 | Formula milk powder for premature infants and preparation method thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011505565.7A Pending CN112640957A (en) | 2020-12-18 | 2020-12-18 | Formula milk powder for premature infants and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN112640957A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112741154A (en) * | 2019-10-30 | 2021-05-04 | 东北农业大学 | Formula liquid milk for premature infants and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107668208A (en) * | 2017-11-13 | 2018-02-09 | 海普诺凯营养品有限公司 | A kind of formula milk for promoting intestinal health |
| CN108522655A (en) * | 2018-04-13 | 2018-09-14 | 内蒙古欧世蒙牛乳制品有限责任公司 | The baby milk and preparation method of micro functional active components in a kind of across-the-board regulation formula |
| CN110881526A (en) * | 2019-11-29 | 2020-03-17 | 内蒙古伊利实业集团股份有限公司 | Composition for promoting iron absorption and application thereof |
-
2020
- 2020-12-18 CN CN202011505565.7A patent/CN112640957A/en active Pending
-
2021
- 2021-12-17 CN CN202111555693.7A patent/CN114097888A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107668208A (en) * | 2017-11-13 | 2018-02-09 | 海普诺凯营养品有限公司 | A kind of formula milk for promoting intestinal health |
| CN108522655A (en) * | 2018-04-13 | 2018-09-14 | 内蒙古欧世蒙牛乳制品有限责任公司 | The baby milk and preparation method of micro functional active components in a kind of across-the-board regulation formula |
| CN110881526A (en) * | 2019-11-29 | 2020-03-17 | 内蒙古伊利实业集团股份有限公司 | Composition for promoting iron absorption and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112640957A (en) | 2021-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103797021B (en) | Oligosaccharide mixture and comprise the food of this mixture, particularly infant formula product | |
| RU2430631C2 (en) | Probiotic oligosaccharides mixture and food product containing it | |
| RU2724590C2 (en) | Nutrient compositions with 2fl and lnnt for use in inducing intestinal microbiota, which is similar to intestinal microbiota of infants in breastfeeding | |
| EP3209308B1 (en) | Activated bifidobacteria and methods of use thereof | |
| EP3197295B1 (en) | Infant formula system with adaptive levels of human milk oligosaccharides (hmos) | |
| Playne et al. | Functional dairy foods and ingredients | |
| AU2016102461A6 (en) | Nutritional compositions and infant formulas comprising Bifidobacterium animalis ssp. lactis and optionally a mix of oligosaccharides for inducing a gut microbiota close to the one of breast fed infants | |
| CN103582426A (en) | Oligosaccharide mixture and food product comprising this mixture, especially infant formula | |
| WO2011096808A1 (en) | Use of sialyl oligosaccharides in weight management | |
| Georgi et al. | Functional glycans and glycoconjugates in human milk | |
| CN112638181B (en) | Bifidobacterium hypoallergenic GOS compositions and methods of providing same involving beta-galactosidase from lactobacillus delbrueckii subsp bulgaricus strain | |
| Quinn et al. | Symposium review: Dairy-derived oligosaccharides—Their influence on host–microbe interactions in the gastrointestinal tract of infants | |
| AU2017211270B2 (en) | Human milk oligosaccharides against later in life excessive fat mass accumulation and related health disorders | |
| CN105899089A (en) | Nutritional composition for use in reducing metabolic stress in infants, decreasing gut permeability and approximating growth rate of breast-fed infants | |
| CN111886332A (en) | Novel bacterium belonging to the genus Bifidobacterium and composition containing the same | |
| CN114097888A (en) | Formula milk powder for premature infants and preparation method thereof | |
| CN112385843A (en) | Balanced nutrition powder containing composite prebiotics and preparation method thereof | |
| CN111565734A (en) | Therapeutic use of lactobacillus plantarum | |
| Strzałkowska et al. | Physico-chemical properties of lactose, reasons for and effects of its intolerance in humans–a review | |
| Yao et al. | Unlocking the mysteries of milk oligosaccharides: Structure, metabolism, and function | |
| Verardo et al. | Oligosaccharides from colostrum and dairy by-products: determination, enrichment, and healthy effects | |
| Nagendra et al. | Effect of feeding infant formulations containing bifidus factors on in vivo proliferation of bifidobacteria and stimulation of intraperitoneal macrophage activity in rats | |
| Dallas et al. | Production and bioactivity of bovine milk oligosaccharides | |
| RU2784624C2 (en) | Breast milk oligosaccharides against excessive accumulation of adipose tissue mass in further life and related health disorders | |
| Bunyatratchata | Prebiotics in Early Life Nutrition: A Qualitative and Quantitative Investigation of Gut Microbiome-Promoting Compounds in Liquid Formulations for Infants and Calves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |